About RhoDx

RhoDx is a St. Louis-based, privately held company founded to improve cancer screening and save lives. The company’s core technologies, PointSuppressor™ and NexGenAbler™, offer several advantages in cancer detection including orders of magnitude improvements in limit of detection, throughput, and sequencing costs when compared to existing methods. Combined, they enable a highly specific, sensitive, and automation-friendly method for quantitative measurement of the mutations that drive cancer within the same tube. Our mission is to leverage these technologies to improve liquid biopsy and enable more scalable, sensitive detection of cancer to dramatically decrease cancer deaths through early, descriptive detection of many cancers. We believe better methods for screening and monitoring cancer will have the biggest impact on patient outcomes this decade.

Contact:
Dr. Charlie Rodi
RhoDx, Inc.
(858) 353-1084
rhodx@rhodx.com